The current shortage of the Aminocaproic Acid injection, 250 mg/mL, 20 mL vial has patients with bleeding disorders and post-surgical patients quite concerned. This injection is crucial for controlling bleeding when blood clots are broken down overly quickly, which occurs often after heart, liver or other surgery, as well as for people who have certain bleeding disorders. Pregnant women who experience placental abruption are commonly dosed with the Aminocaproic Acid injection to help control bleeding safely as well. As an effectual medication in a class deemed hemostatics, Aminocaproic Acid is typically prescribed as a once per hour injection in a hospital setting for roughly 8 hours, or until the bleeding has stopped. Patients who experience ongoing bleeding will receive injections every 3-6 hours until this dangerous situation is controlled. The Aminocaproic Acid shortage is proving to be a great concern for hospitals and surgery centers around the globe, given the drug’s efficacious and lifesaving qualities.
Practitioners in the emergency medicine field have also found the Aminocaproic Acid injection to be integral for treating patients with sudden eye injuries which encompass bleeding of the eye, and after surgery for patients with prostate or cervical cancer. Adverse effects are possible, but uncommon. Most common side effects from the Aminocaproic Acid injection include nausea, vomiting, diarrhea, dizziness and headache. Research regarding the use of Aminocaproic Acid to treat patients who have experienced acute traumatic brain injuries has been favorable. A compilation of data published in The Cochrane Library online offered consistently effective results from the use of Aminocaproic Acid when treating people with traumatic brain injuries, or traumatic brain injuries. Further research regarding the use of hemostatic medications, like Aminocaproic Acid, for treating patients with traumatic brain injuries was recommended.
If you are concerned about the Aminocaproic Acid shortage, you are not alone. If you are looking for a reputable API supplier based in the U.S., then LGM Pharma can assist you with your needs. LGM Pharma provides the Aminocaproic Acid CAS# 60-32-2 API for research and development purposes. Clients can be assured of continuous support throughout the R&D process, as well as quality API products.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.